ABSK211 / Abbisko - LARVOL DELTA

A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration (clinicaltrials.gov) - P1 | N=247 | Recruiting | Sponsor: Abbisko Therapeutics Co, Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Oncology • Solid Tumor • KRAS

…Abbisko Therapeutics…announced that the China National Medical Products Administration ('NMPA') has cleared the Investigational New Drug ('IND') application for ABSK211, an oral and highly potent small-molecule pan-KRAS inhibitor with broad alteration coverage, for the treatment of patients with advanced solid tumors harboring KRAS alterations (HKEXnews)

Trial status • Solid Tumor

A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration (clinicaltrials.gov) - P1 | N=247 | Not yet recruiting | Sponsor: Abbisko Therapeutics Co, Ltd

First-in-human • New P1 trial • Oncology • Solid Tumor • KRAS

Abbisko Therapeutics Announces IND Clearance from the FDA for Oral Small Molecule pan-KRAS Inhibitor ABSK211 (HKEXnews) - "The cleared study is an open-label Phase I clinical trial designed to assess the safety, tolerability, efficacy and pharmacokinetics of ABSK211 in patients with advanced solid tumors harboring KRAS alterations."

IND • New P1 trial • Solid Tumor

Preclinical characterization of ABSK211: A highly potent, orally bioavailable and selective pan-KRAS inhibitor with broad and robust activity in KRAS-driven tumors (AACR 2026) - "Additionally, ABSK211 exhibited robust anti-tumor activity in xenograft models with other KRAS mutations, such as KRAS G12D/S and KRAS G13D. ABSK211 is currently undergoing IND-enabling studies; its superior preclinical profile supports its advancement into clinical studies."

Preclinical • Colorectal Cancer • Lung Cancer • Oncology • Solid Tumor • KRAS

ABSK211, a highly potent and orally available pan-KRAS inhibitor, demonstrates robust antitumor efficacy in combination with multiple agents (AACR 2026) - "These findings provide a strong preclinical rationale for advancing these combinations of ABSK211 into clinical development to improve outcomes for patients with KRAS-mutant cancers."

Clinical • Combination therapy • IO biomarker • Colorectal Cancer • Oncology • Solid Tumor • KRAS

Abbisko Therapeutics…announced that six preclinical study updates from its proprietary pipeline have been selected for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting (Abbisko Therap Press Release)

Preclinical • Solid Tumor